Literature DB >> 11022060

Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial.

J P Broderick1, M Lu, R Kothari, S R Levine, P D Lyden, E C Haley, T G Brott, J Grotta, B C Tilley, J R Marler, M Frankel.   

Abstract

BACKGROUND AND
PURPOSE: We sought to identify the most powerful binary measures of the treatment effect of tissue plasminogen activator (tPA) in the National Institute of Neurological Disorders and Stroke (NINDS) rTPA Stroke Trial.
METHODS: Using the Classification and Regression Tree (CART) algorithm, we evaluated binary cut points and combination of binary cut points with the 4 clinical scales and head CT imaging measures in the NINDS tPA Stroke Trial at 4 times after treatment: 2 hours, 24 hours, 7 to 10 days, and 3 months. The first analysis focused on detecting evidence of "early activity" of tPA with the use of outcome measures derived from the 2-hour and 24-hour clinical and radiographic measures. The second analysis focused on longer-term outcome and "efficacy" and used outcome measures derived from 7- to 10-day and 3-month measures. After identifying the cut points with the ability to classify patients into the tPA and placebo groups using part I data from the trial, we then used data from part II of the trial to validate the results.
RESULTS: Of the 5 most powerful outcome measures for early activity of tPA, 4 involved the National Institutes of Health Stroke Scale (NIHSS) score at 24 hours or changes in the NIHSS score from baseline to 24 hours. The best overall single outcome measure was an NIHSS score </=2 at 24 hours, which provided an odds ratio of 5.4 (95% CI, 2.4 to 12.1) and a projected sample size of 58 per treatment group assuming an alpha of 0.05 (2-sided test) and a power of 80% using part I data. The top 2 and 3 of the top 5 outcome measures for detecting the longer-term efficacy of tPA also involved the NIHSS score. A Rankin score of 0 or 1 at 3 months was the third most powerful outcome measure. Outcome measures identified by CART from part I data were not as sensitive in detecting the effectiveness of tPA when applied to part II data.
CONCLUSIONS: Measures using the NIHSS and a Rankin score </=1 were the most sensitive discriminators of the effectiveness of tPA in the NINDS tPA Stroke Trial compared with the other clinical and radiological measures. The outcome measures identified in this exploratory analysis (eg, NIHSS score </=2 at 24 hours) would be best used as an outcome measure in future phase II trials of recanalization begun within the first 3 hours after stroke onset, with inclusion and exclusion criteria similar to those in the NINDS tPA Stroke Trial.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11022060     DOI: 10.1161/01.str.31.10.2335

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  30 in total

1.  Endovascular mechanical clot retrieval in a broad ischemic stroke cohort.

Authors:  D Kim; R Jahan; S Starkman; A Abolian; C S Kidwell; F Vinuela; G R Duckwiler; B Ovbiagele; P M Vespa; S Selco; V Rajajee; J L Saver
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

2.  What should be defined as good outcome in stroke trials; a modified Rankin score of 0-1 or 0-2?

Authors:  N Weisscher; M Vermeulen; Y B Roos; R J de Haan
Journal:  J Neurol       Date:  2008-03-14       Impact factor: 4.849

3.  Prognostic Value of the 24-Hour Neurological Examination in Anterior Circulation Ischemic Stroke: A post hoc Analysis of Two Randomized Controlled Stroke Trials.

Authors:  Srikant Rangaraju; Michael Frankel; Tudor G Jovin
Journal:  Interv Neurol       Date:  2016-02-19

4.  Discharge destination as a surrogate for Modified Rankin Scale defined outcomes at 3- and 12-months poststroke among stroke survivors.

Authors:  Adnan I Qureshi; Saqib A Chaudhry; Biggya L Sapkota; Gustavo J Rodriguez; M Fareed K Suri
Journal:  Arch Phys Med Rehabil       Date:  2012-03-21       Impact factor: 3.966

5.  Measuring Outcome After Stroke: More Lessons Learned Again.

Authors:  Patrick D Lyden
Journal:  Stroke       Date:  2020-02-27       Impact factor: 7.914

6.  Microcatheter to recanalization (procedure time) predicts outcomes in endovascular treatment in patients with acute ischemic stroke: when do we stop?

Authors:  A E Hassan; S A Chaudhry; J T Miley; R Khatri; S A Hassan; M F K Suri; A I Qureshi
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-19       Impact factor: 3.825

7.  Resting-State Functional Connectivity Magnetic Resonance Imaging and Outcome After Acute Stroke.

Authors:  Josep Puig; Gerard Blasco; Angel Alberich-Bayarri; Gottfried Schlaug; Gustavo Deco; Carles Biarnes; Marian Navas-Martí; Mireia Rivero; Jordi Gich; Jaume Figueras; Cristina Torres; Pepus Daunis-I-Estadella; Celia L Oramas-Requejo; Joaquín Serena; Cathy M Stinear; Amy Kuceyeski; Carles Soriano-Mas; Götz Thomalla; Marco Essig; Chase R Figley; Bijoy Menon; Andrew Demchuk; Kambiz Nael; Max Wintermark; David S Liebeskind; Salvador Pedraza
Journal:  Stroke       Date:  2018-10       Impact factor: 7.914

8.  Profiles of the National Institutes of Health Stroke Scale items as a predictor of patient outcome.

Authors:  Heidi Sucharew; Jane Khoury; Charles J Moomaw; Kathleen Alwell; Brett M Kissela; Samir Belagaje; Opeolu Adeoye; Pooja Khatri; Daniel Woo; Matthew L Flaherty; Simona Ferioli; Laura Heitsch; Joseph P Broderick; Dawn Kleindorfer
Journal:  Stroke       Date:  2013-05-23       Impact factor: 7.914

Review 9.  Clinical trial design for endovascular ischemic stroke intervention.

Authors:  Osama O Zaidat; David S Liebeskind; Randall C Edgell; Catherine M Amlie-Lefond; Junaid S Kalia; Andrei V Alexandrov
Journal:  Neurology       Date:  2012-09-25       Impact factor: 9.910

10.  Society of Vascular and Interventional Neurology (SVIN) Stroke Interventional Laboratory Consensus (SILC) Criteria: A 7M Management Approach to Developing a Stroke Interventional Laboratory in the Era of Stroke Thrombectomy for Large Vessel Occlusions.

Authors:  Tanzila Shams; Osama Zaidat; Dileep Yavagal; Andrew Xavier; Tudor Jovin; Vallabh Janardhan
Journal:  Interv Neurol       Date:  2016-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.